Trials / Completed
CompletedNCT06626165
Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
Mirikizumab Therapy is Effective for Patients With Moderate to Severe Ulcerative Colitis Patients Whose Geboes Score Grade is ≥3.2) on Endoscopic Biopsy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Showa Inan General Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to confirm that Mirikizumab therapy may provide clinical, endoscopic, and histopathologic improvements in patients with moderate to severe UC refractory to maintenance therapy when high neutrophilic infiltration in epithelium of the colonic mucosa (Geboes score Grade ≥3.2) on endoscopic biopsy is found.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirikizumab | Mirikizmgab will be administered based on the result of Geboes score Grade ≥ 3.2. |
| DRUG | Vedolizumab | Vedolizmab will be administered based on the result of Geboes score Grade 3.1. |
Timeline
- Start date
- 2024-07-20
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
- First posted
- 2024-10-03
- Last updated
- 2025-10-20
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06626165. Inclusion in this directory is not an endorsement.